Cargando…
Quantitative Systems Pharmacology Model of a Masked, Tumor‐Activated Antibody
PROBODY therapeutics (Pb‐Tx) are protease‐activatable prodrugs of monoclonal antibodies (mAbs) designed to target tumors where protease activity is elevated while avoiding normal tissue. They are composed of a parental mAb, a mask that inhibits antibody binding to target, and a protease‐cleavable su...
Autores principales: | Stroh, Mark, Sagert, Jason, Burke, John M., Apgar, Joshua F., Lin, Lin, Millard, Bjorn L., Michael Kavanaugh, W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6765697/ https://www.ncbi.nlm.nih.gov/pubmed/31250966 http://dx.doi.org/10.1002/psp4.12448 |
Ejemplares similares
-
Quantitative systems pharmacology model of GITR‐mediated T cell dynamics in tumor microenvironment
por: Ji, Yan, et al.
Publicado: (2023) -
Quantitative systems toxicology
por: Bloomingdale, Peter, et al.
Publicado: (2017) -
Quantitative systems pharmacology model for Alzheimer’s disease to predict the effect of aducanumab on brain amyloid
por: Lin, Lin, et al.
Publicado: (2022) -
Quantitative Systems Pharmacology Model of hUGT1A1‐modRNA Encoding for the UGT1A1 Enzyme to Treat Crigler‐Najjar Syndrome Type 1
por: Apgar, Joshua F., et al.
Publicado: (2018) -
CORRIGENDUM: Quantitative Systems Pharmacology Model of hUGT1A1‐modRNA Encoding for the UGT1A1 Enzyme to Treat Crigler‐Najjar Syndrome Type 1
por: Apgar, J.F., et al.
Publicado: (2020)